MYGN · Myriad Genetics
The AI's read
A share-price move does not show whether Myriad's tests, sales, or finances changed. This roundup reports no company news or reason for the move, so it does not change how we read the business.
Myriad Genetics shares rose about 37%, but the article gives no business update or reason for the move. The share-price change alone does not alter the company's outlook.
A share-price move does not show whether Myriad's tests, sales, or finances changed. This roundup reports no company news or reason for the move, so it does not change how we read the business.
iBio shares rose about 17%, but the article gives no business update or reason for the move. The share-price change alone does not alter the company's outlook.
Concord Medical Services shares rose about 18%, but the article gives no business update or reason for the move. The share-price change alone does not alter the company's outlook.
SCWorx shares rose about 43%, but the article gives no business update or reason for the move. The share-price change alone does not alter the company's outlook.
Anbio Biotechnology shares rose about 22%, but the article gives no business update or reason for the move. The share-price change alone does not alter the company's outlook.
Clene shares rose about 21%, but the article gives no business update or reason for the move. The share-price change alone does not alter the company's outlook.
Follow Myriad Genetics (MYGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MYGN